Clinical Trials
104 trialsNCT07213804 2026-05-27
FRAmework-01
Eli Lilly and Company
Phase 3 Recruiting
NCT01552434 2026-05-15
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT05919264 2026-05-12
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Parabilis Medicines, Inc.
Phase 1/2 Recruiting
NCT06792695 2026-05-11
CANTOR
AstraZeneca
Phase 2 Recruiting
NCT07222800 2026-04-21
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Pfizer
Phase 3 Recruiting
NCT01187199 2026-04-16
Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT06625775 2026-04-13
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1 Recruiting
NCT05665348 2026-03-09
TRIPLET
Federation Francophone de Cancerologie Digestive
Phase 2/3 Completed
NCT07407465 2026-02-17
CHIMERA
Gruppo Oncologico del Nord-Ovest
Phase 2 Recruiting
NCT04449874 2026-02-12
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
Genentech, Inc.
Phase 1 Active not recruiting
NCT06268015 2026-02-05
BBOpCo
Duke University
Phase 2 Active not recruiting
NCT03307785 2025-11-25
Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042
Tesaro, Inc.
Phase 1 Completed
NCT06311851 2025-11-25
Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases
Pardis Noor Medical Imaging and Cancer Center
Phase 1/2 Recruiting
NCT05678257 2025-09-12
A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer
NuCana plc
Phase 2 Terminated
NCT06680258 2025-09-03
A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy
Tempest Therapeutics
Phase 3 Not yet recruiting
NCT02671435 2025-07-22
A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors
MedImmune LLC
Phase 1/2 Active not recruiting
NCT02885753 2025-07-09
OSCAR
Federation Francophone de Cancerologie Digestive
Phase 3 Recruiting
NCT04553692 2025-03-28
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
IGM Biosciences, Inc.
Phase 1 Terminated
NCT03024437 2025-03-20
Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma
Indiana University
Phase 1/2 Terminated
NCT05087992 2025-02-19
A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers
Boehringer Ingelheim
Phase 1 Completed
NCT02794571 2024-12-05
Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors
Genentech, Inc.
Phase 1 Completed
NCT05824975 2024-11-25
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
GI Innovation, Inc.
Phase 1/2 Recruiting
NCT06448364 2024-11-06
LTbR
Pfizer
Phase 1 Terminated
NCT04999761 2024-09-25
AB122 Platform Study
Taiho Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT03475004 2024-09-19
Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer
University of Colorado, Denver
Phase 2 Completed
NCT02743221 2024-08-20
TASCO1
Servier
Phase 2 Completed
NCT06539559 2024-08-06
Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT02848443 2024-07-25
Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer
Servier
Phase 1 Completed
NCT02842580 2024-07-10
HIGH-LIGHT
Federation Francophone de Cancerologie Digestive
Phase 2 Terminated
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT04817956 2024-02-29
IMPRESS-N
Oslo University Hospital
Phase 2 Recruiting
NCT03698461 2024-01-31
CLIMB
Asan Medical Center
Phase 2 Completed
NCT06192680 2024-01-18
Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer
Harbin Medical University
Phase 2 Not yet recruiting
NCT02803203 2023-09-22
Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT05904457 2023-06-15
BRISK
Asan Medical Center
Phase 2 Unknown
NCT01718873 2023-04-12
OBELICS
National Cancer Institute, Naples
Phase 3 Completed
NCT00819780 2022-12-06
PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors
Amgen
Phase 2 Completed
NCT01015222 2022-11-23
Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01759238 2022-07-01
OLGA
Universitätsklinikum Hamburg-Eppendorf
Phase 2 Terminated
NCT00321100 2022-01-12
Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab
Fox Chase Cancer Center
Phase 2 Terminated
NCT01442649 2022-01-11
Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab
UNICANCER
Phase 2 Completed
NCT02015923 2021-03-16
CCRe-IV
Hospital Universitari de Bellvitge
Phase 4 Terminated
NCT02363751 2021-03-09
BEVABEL
UNICANCER
Phase 2 Completed
NCT01327612 2021-02-21
Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)
Amgen
Phase 2 Completed
NCT01197170 2021-01-22
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01858649 2020-10-22
BEV-ONCO2012
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase 2 Completed
NCT02226289 2020-09-02
BATTLE
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2 Unknown
NCT04380103 2020-05-08
A Phase I/II Study of XELOXIRI and Bevacizumab as First-line Treatment in Metastatic Colorectal Cancer
ChineseAMS
Phase 1/2 Unknown
NCT00281528 2019-11-22
Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer
Celgene
Phase 2 Terminated
NCT01898130 2019-09-17
Bevacizumab in Pats w/ Recurrent ST Brain Metas Who Have Failed Whole Brain Radiation Therapy
Northwestern University
Phase 2 Completed